Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer

Tatsuro Okamoto, Tomomi Nakamura, Jiro Ikeda, Riichiroh Maruyama, Fumihiro Shoji, Tetsuro Miyake, Hiroshi Wataya, Yukito Ichinose

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, which has a tumour reducing effect in non-small cell lung cancer (NSCLC). In this study, we retrospectively reviewed the clinical data from 105 patients with advanced NSCLC treated with gefitinib at our department between May 2002 and April 2004. The overall response rate was 27.8% and the median survival time was 9.3 months. Pretreatment characteristics suggested that those with no history of smoking or an elevated serum carcinoembryonic antigen (CEA) level were more likely to be sensitive to gefitinib (P = 0.009). A multivariate analysis indicated good PS (P < 0.0001) and elevated serum CEA level (P = 0.0027) to be independent prognostic factors. These data show that the serum CEA level can be a predictive factor for the efficacy of gefitinib treatment while it is also a prognostic factor for advanced NSCLC patients undergoing this treatment.

Original languageEnglish
Pages (from-to)1286-1290
Number of pages5
JournalEuropean Journal of Cancer
Volume41
Issue number9
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Carcinoembryonic Antigen
Non-Small Cell Lung Carcinoma
Serum
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Multivariate Analysis
Smoking
Survival
gefitinib
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. / Okamoto, Tatsuro; Nakamura, Tomomi; Ikeda, Jiro; Maruyama, Riichiroh; Shoji, Fumihiro; Miyake, Tetsuro; Wataya, Hiroshi; Ichinose, Yukito.

In: European Journal of Cancer, Vol. 41, No. 9, 01.01.2005, p. 1286-1290.

Research output: Contribution to journalArticle

Okamoto, T, Nakamura, T, Ikeda, J, Maruyama, R, Shoji, F, Miyake, T, Wataya, H & Ichinose, Y 2005, 'Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer', European Journal of Cancer, vol. 41, no. 9, pp. 1286-1290. https://doi.org/10.1016/j.ejca.2005.03.011
Okamoto, Tatsuro ; Nakamura, Tomomi ; Ikeda, Jiro ; Maruyama, Riichiroh ; Shoji, Fumihiro ; Miyake, Tetsuro ; Wataya, Hiroshi ; Ichinose, Yukito. / Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. In: European Journal of Cancer. 2005 ; Vol. 41, No. 9. pp. 1286-1290.
@article{2c39f23d184f4379a04f183a4452f621,
title = "Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer",
abstract = "Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, which has a tumour reducing effect in non-small cell lung cancer (NSCLC). In this study, we retrospectively reviewed the clinical data from 105 patients with advanced NSCLC treated with gefitinib at our department between May 2002 and April 2004. The overall response rate was 27.8{\%} and the median survival time was 9.3 months. Pretreatment characteristics suggested that those with no history of smoking or an elevated serum carcinoembryonic antigen (CEA) level were more likely to be sensitive to gefitinib (P = 0.009). A multivariate analysis indicated good PS (P < 0.0001) and elevated serum CEA level (P = 0.0027) to be independent prognostic factors. These data show that the serum CEA level can be a predictive factor for the efficacy of gefitinib treatment while it is also a prognostic factor for advanced NSCLC patients undergoing this treatment.",
author = "Tatsuro Okamoto and Tomomi Nakamura and Jiro Ikeda and Riichiroh Maruyama and Fumihiro Shoji and Tetsuro Miyake and Hiroshi Wataya and Yukito Ichinose",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2005.03.011",
language = "English",
volume = "41",
pages = "1286--1290",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer

AU - Okamoto, Tatsuro

AU - Nakamura, Tomomi

AU - Ikeda, Jiro

AU - Maruyama, Riichiroh

AU - Shoji, Fumihiro

AU - Miyake, Tetsuro

AU - Wataya, Hiroshi

AU - Ichinose, Yukito

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, which has a tumour reducing effect in non-small cell lung cancer (NSCLC). In this study, we retrospectively reviewed the clinical data from 105 patients with advanced NSCLC treated with gefitinib at our department between May 2002 and April 2004. The overall response rate was 27.8% and the median survival time was 9.3 months. Pretreatment characteristics suggested that those with no history of smoking or an elevated serum carcinoembryonic antigen (CEA) level were more likely to be sensitive to gefitinib (P = 0.009). A multivariate analysis indicated good PS (P < 0.0001) and elevated serum CEA level (P = 0.0027) to be independent prognostic factors. These data show that the serum CEA level can be a predictive factor for the efficacy of gefitinib treatment while it is also a prognostic factor for advanced NSCLC patients undergoing this treatment.

AB - Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, which has a tumour reducing effect in non-small cell lung cancer (NSCLC). In this study, we retrospectively reviewed the clinical data from 105 patients with advanced NSCLC treated with gefitinib at our department between May 2002 and April 2004. The overall response rate was 27.8% and the median survival time was 9.3 months. Pretreatment characteristics suggested that those with no history of smoking or an elevated serum carcinoembryonic antigen (CEA) level were more likely to be sensitive to gefitinib (P = 0.009). A multivariate analysis indicated good PS (P < 0.0001) and elevated serum CEA level (P = 0.0027) to be independent prognostic factors. These data show that the serum CEA level can be a predictive factor for the efficacy of gefitinib treatment while it is also a prognostic factor for advanced NSCLC patients undergoing this treatment.

UR - http://www.scopus.com/inward/record.url?scp=20444489613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444489613&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.03.011

DO - 10.1016/j.ejca.2005.03.011

M3 - Article

VL - 41

SP - 1286

EP - 1290

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0959-8049

IS - 9

ER -